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Summary
Background.  —  Endovascular  stenting  is  a  recognised  treatment  strategy  for  aortic  coarctation
(CoA) in  adults.  We  assessed  systemic  hypertension  control  and  the  need  for  antihypertensive
therapy after  CoA  stenting  in  adults.
Methods.  —  Data  were  collected  prospectively  on  54  patients  (36  men;  mean  age:  34  ±  16  years)
who underwent  endovascular  stenting  for  CoA  over  a  7-year  period.  Five  patients  were  excluded
as they  did  not  attend  follow-up  appointments.  Patients  underwent  clinical  examination,  includ-
ing right  arm  systolic  blood  pressure  (SBP)  and  24-hour  ambulatory  blood  pressure  monitoring
at baseline,  6—12  weeks  and  9—12  months.
Results.  —  There  was  a  signiﬁcant  fall  in  mean  peak-to-peak  systolic  gradient  (PG)  across  the
CoA after  stenting  (26  ±  11  mmHg  vs.  5  ±  4  mmHg;  P  <  0.01).  There  were  successive  reductions
in right  arm  SBP  and  ambulatory  SBP  at  baseline,  6—12  weeks  and  9—12  months  post-procedure
(right arm:  155  ±  18  mmHg  vs.  137  ±  17  mmHg  vs.  142  ±  16  mmHg,  respectively;  all  P-values
<0.01; ambulatory:  142  ±  14  mmHg  vs.  132  ±  16  mmHg  vs.  131  ±  15  mmHg,  respectively;  all
P-values <0.01).  Twenty-four  patients  had  severe  CoA  (PG  >25  mmHg  before  stenting);  baseline
Abbreviations: AUC, area under the curve; CI, conﬁdence interval; CoA, aortic coarctation; PG, peak-to-peak systolic gradient;
OC, receiver-operating characteristic; SBP, systolic blood pressure.
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SBP  was  signiﬁcantly  higher  in  severe  versus  non-severe  patients  (160  mmHg  vs.  148  mmHg;
P =  0.02).  The  absolute  reduction  in  PG  after  stenting  was  signiﬁcantly  higher  in  the  severe
group (31  ±  7  mmHg  vs.  14  ±  5  mmHg;  P  <  0.0001),  but  there  was  no  signiﬁcant  difference  in  SBP
between groups  at  6—12  weeks  (141  mmHg  vs.  135  mmHg;  P  =  0.21)  or  9—12  months  (139  mmHg
vs. 139  mmHg;  P  =  0.96).
Conclusion.  —  Endovascular  stenting  of  CoA  results  in  a  signiﬁcant  reduction  in  SBP  at  6—12
weeks, which  is  sustained  at  9—12  months,  with  similar  outcomes  in  severe  and  non-severe  CoA
groups.
© 2015  Elsevier  Masson  SAS.  All  rights  reserved.
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Résumé
Justiﬁcation.  —  Le  stenting  endovasculaire  est  une  stratégie  thérapeutique  validée  de  traite-
ment de  la  coarctation  aortique  chez  l’adulte.  Nous  avons  évalué  le  contrôle  de  l’hypertension
artérielle  et  la  nécessité  d’un  traitement  antihypertenseur  chez  des  patients  porteurs  d’une
coarctation  aortique  traités  par  stenting.
Méthode.  —  Les  données  ont  été  collectées  de  fac¸on  prospective  chez  54  patients,  36  hommes,
âge moyen  de  34  ±  16  ans,  qui  ont  bénéﬁcié  d’un  stenting  endovasculaire  pour  coarctation
aortique pendant  une  période  de  suivi  de  7  ans.  Cinq  patients  ont  été  exclus,  car  ils  n’étaient
pas suivis  de  fac¸on  régulière.  Les  patients  ont  été  évalués  cliniquement,  avec  mesures  de  la
pression  artérielle  au  bras  droit  ainsi  qu’un  enregistrement  ambulatoire  de  la  pression  artérielle
sur 24  heures,  à  l’état  basal,  à  6—12  semaines  et  à  9—12  mois.
Résultats.  —  Nous  avons  observé  une  diminution  signiﬁcative  du  gradient  intra-aortique  pic  à
pic moyen  après  le  stenting  (26  ±  11  mmHg  versus  5  ±  4  mmHg  ;  p  <  0,01).  Nous  avons  observé
une réduction  signiﬁcative  de  la  pression  artérielle  au  bras  droit  et  de  la  pression  artérielle
ambulatoire  à  l’état  basal,  à  6—12  semaines  et  à  9—12  mois  au  décours  de  la  procédure
(bras droit  :  155  ±  18  mmHg  versus  137  ±  17  mmHg  versus  142  ±  16  mmHg  respectivement  ;
valeurs de  p  <  0,01).  Pour  la  pression  artérielle  ambulatoire,  les  chiffres  sont  respectivement  de
142 ±  14  mmHg  versus  132  ±  16  mmHg  versus  131  ±  15  mmHg  (valeurs  de  p  <  0,01).  Vingt-quatre
patients  ayant  une  coarctation  aortique  sévère  avec  un  gradient  intra-aortique  >  25  mmHg  avant
le stenting  ont  bénéﬁcié  de  fac¸on  très  signiﬁcative  de  cette  procédure  de  stenting  ;  la  pres-
sion artérielle  à  l’état  basal  était  signiﬁcativement  plus  élevée  que  chez  les  patients  ayant  un
gradient en  dec¸à de  25  mmHg  (160  mmHg  versus  148  mmHg  ;  p  =  0,02).  La  réduction  absolue  du
gradient de  pression  aortique  au  décours  du  stenting  était  signiﬁcativement  plus  important  dans
le groupe  ayant  à  l’état  basal  la  coarctation  la  plus  sévère  (31  ±  7  mmHg  versus  14  ±  5  mmHg
; p  <  0,0001).  Il  n’y  avait  pas  cependant  de  différence  signiﬁcative  de  pression  artérielle  sys-
tolique entre  les  groupes  à  6—12  semaines  (141  mmHg  versus  135  mmHg  ;  p  =  0,21)  ou  à  9—12
mois (139  mmHg  versus  139  mmHg  ;  p  =  0,96).
Conclusion.  —  Le  stenting  endovasculaire  de  la  coarctation  aortique  chez  l’adulte  conduit  à  une
réduction signiﬁcative  du  niveau  de  pression  artérielle  à  6—10  semaines,  se  maintient  à  9—12
mois avec  un  suivi  similaire  qu’il  s’agisse  de  patients  ayant  ou  non  une  coarctation  aortique
sévère à  l’état  basal.
©  2015  Elsevier  Masson  SAS.  Tous  droits  réservés.
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Aortic  coarctation  (CoA)  is  a  congenital  narrowing  of  the
upper  descending  thoracic  aorta  adjacent  to  the  site  of
attachment  of  the  ductus  arteriosus  (ligamentum  arterio-
sum)  [1].  CoA  represents  5—10%  of  all  congenital  cardiac
lesions  [2].  CoA  has  a  male  predominance  and  has  been
associated  with  conditions  that  include  gonadal  dysgene-
sis  (Turner’s  syndrome),  Shone’s  complex,  bicuspid  aortic
valve,  intracranial  aneurysms,  patent  ductus  arteriosus,
g
a
aentricular  septal  defect  and  mitral  stenosis  or  regurgita-
ion  [1,3].  If  left  untreated,  CoA  is  associated  with  high
orbidity  and  mortality  [4,5].  The  ﬁrst  surgical  repair  for
oA  was  performed  in  1945  [6].  Various  surgical  techniques
ere  developed  across  age  groups,  including  resection  with
nd-to-end  anastomosis,  extended  end-to-end  anastomo-
is,  end-to-side  anastomosis,  extra-anatomical  bypass,  tube
raft  replacement,  patch  augmentation  and  subclavian  ﬂap
ortoplasty  [1].  Surgical  repair  is  performed  depending  on
ge  of  presentation,  ranging  from  newborns  to  adults  [7].
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atients  can  develop  restenosis  of  the  previously  repaired
oA  with  the  passage  of  time,  because  of  ﬁbrous  scar  tissue
r  residual  ductal  tissue  contracting.
In  1982  [8],  the  ﬁrst  percutaneous  balloon  dilatation  was
uccessfully  performed  in  an  infant  and,  since  then,  has  also
een  successfully  performed  in  recurrent  CoA  [9—11].  While
alloon  dilatation  showed  promising  results  in  the  short-
erm,  because  of  the  elastic  recoil  properties  of  the  aorta,
estenosis  was  common,  being  reported  in  up  to  20—30%  of
atients  [10,11].  In  1991,  O’Laughlin  et  al.  [12]  successfully
sed  balloon-expandable  endovascular  stents,  and  this  tech-
ique  is  currently  an  established  management  strategy  in
dults  with  CoA  [13—16].
The  main  objectives  of  this  study  were  to  assess  systemic
ypertension  outcomes  and  the  need  for  antihypertensive
herapy  in  adolescent  and  adult  patients  undergoing  primary
tenting  for  CoA.
ethods
tudy population
he  data  were  collected  prospectively  for  54  adolescent  and
dult  patients  who  underwent  transcatheter  stenting  of  CoA
ver  a  7-year  period.  These  patients  were  followed  up  as
art  of  a  non-randomized  observational  protocol.  Informed
ritten  consent  was  obtained  from  all  patients  before  the
tenting  procedure,  according  to  local  guidelines.  Patients
ere  deﬁned  as  being  hypertensive  if  they  had  blood  pres-
ure  readings  (right  upper  limb)  >140/90  mmHg  on  more
han  one  occasion  at  rest  [17].  Blood  pressure  was  mea-
ured  at  6—12  weeks  and  9—12  months  at  clinical  follow-up,
nd  included  outpatient  ambulatory  blood  pressure  monitor-
ng.  Clinical  blood  pressure  was  measured  10  minutes  after
rrival  of  the  patient  at  the  outpatient  department,  in  an
pright  position  in  the  right  upper  limb  with  an  automated
uff.
tent deployment technique
 single  lead  operator  performed  all  procedures  with  either
overed  or  uncovered  stents,  according  to  operator  pref-
rence  and  angiographic  ﬁndings.  All  procedures  were
erformed  under  general  anaesthesia.  The  covered  stents
sed  were  the  Cheatham  Platinum  (CP)  stentTM (NuMED,
opkinton,  NY,  USA)  and  the  Adventa  V12TM stent  (Atrium,
ijdrecht,  Netherlands);  the  uncovered  stents  used  were
he  MaxTM LD  stent  (EV3,  Plymouth,  MN,  USA),  the  PALMAZTM
tent  (Cordis  [Johnson  &  Johnson],  Roden,  the  Nether-
ands),  the  CP  StentTM (NuMED,  Hopkinton,  NY,  USA)  and  the
OSTENTTM (Abbott  Vascular  Devices,  Santa  Clara,  CA,  USA).
he  balloons  used  for  deployment  of  non-premounted  stents
ncluded  the  balloon-in-balloon  (BIBTM;  NuMED,  Hopkinton,
Y,  USA)  and  CristalTM balloons  (Balt,  Montmorency,  France).
Vascular  access  was  achieved  from  the  femoral  artery
n  all  patients.  Further  arterial  access  was  achieved  using
he  right  radial  artery  in  all  patients  except  one,  in  whom
rachial  artery  access  was  obtained.  In  two  patients,  the
oA  site  could  not  be  crossed  from  the  femoral  approach,
nd  the  wire  was  snared  from  the  femoral  artery  after
ntegrade  crossing  of  the  coarctation  from  an  upper  limb
n
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essel.  Femoral  arterial  access  sites  were  preclosed  using
 Perclose  A-TTM or  ProglideTM device  (Abbott  Vascular
evices,  Santa  Clara,  CA,  USA)  in  49  (91%)  patients.  Patients
eceived  5000  IU  heparin.  Aortic  pressures  were  simulta-
eously  recorded  in  the  ascending  aorta  and  descending
horacic  aorta  to  measure  the  peak-to-peak  systolic  gradient
PG)  across  the  CoA  segment.  An  aortic  arch  angiogram  was
aken  in  the  left  lateral  and  right  anterior  oblique  views.
easurements  were  then  obtained  from  the  images,  includ-
ng  the  diameter  of  the  aorta  proximal  and  distal  to  the
ite  of  obstruction.  The  diameter  of  the  balloon  was  chosen
o  equal  that  of  the  normal  portion  of  the  transverse  arch
r  proximal  isthmus  at  the  level  of  the  take  off  of  the  left
ubclavian  artery.
The  location  of  the  CoA  relative  to  landmarks  within
he  chest  was  noted  for  reference  during  positioning  and
mplantation.  Implantation  was  performed  using  standard
echniques.  After  successful  deployment  of  the  CoA  stent,
he  femoral  artery  access  site  was  closed  with  the  Perclose
-TTM or  ProglideTM preclosure  device.
Major  complications  were  deﬁned  as  mortality  or
omplications  requiring  surgical  intervention  —  either  car-
iac  or  vascular  —  including  the  need  for  blood  transfusions.
tatistical analysis
nalysis  was  performed  using  SPSS  17.0  (SPSS,  Chicago,  IL,
SA).  Group  means  were  compared  using  paired  or  unpaired
tudent’s  t  tests  as  appropriate.  Absolute  PG  reduction
baseline  PG  —  post-stenting  PG)  and  percentage  PG
eduction  ([absolute  PG  reduction/baseline  PG]  ×  100)  were
alculated  for  each  procedure.  The  correlations  between
aseline  PG  and  baseline  systolic  blood  pressure  (SBP),  and
etween  PG  reduction  (absolute  and  percentage  change)
nd  SBP  reduction  (baseline  —  post-stenting  SBP)  at  6—12
eeks  and  9—12  months  were  assessed  using  Pearson’s  corre-
ation  coefﬁcients.  Additionally,  the  predictive  accuracy  of
bsolute  and  percentage  PG  reduction  to  predict  adequate
BP  control  (<140/90  mmHg)  was  determined  using  receiver-
perating  characteristic  (ROC)  analysis,  and  expressed  as
rea  under  the  curve  (AUC).  To  determine  statistical  sig-
iﬁcance,  various  AUCs  were  compared  with  0.5  and  their
5%  conﬁdence  intervals  (CIs)  calculated.  Based  on  inva-
ive  haemodynamic  data  we  divided  patients  into  severe
oA  (PG  >25  mmHg)  and  non-severe  CoA  (PG  ≤25  mmHg)
roups  for  comparison.  All  statistical  tests  were  two-tailed
nd  a  P-value  <0.05  was  considered  signiﬁcant.  Stepwise  uni-
ariate  and  multivariable  logistic  regression  analyses  were
erformed  for  the  outcome  of  SBP  <140  mmHg  at  12  months
sing  the  following  variables:  age,  sex,  preprocedural  SBP,
reprocedural  PG,  post-procedural  PG,  absolute  and  per-
entage  PG  reduction.  An  alpha  level  of  0.05  was  used  for
ntry  into  multivariable  analysis.
tepwise logistic regression
n  univariate  logistic  regression,  only  preprocedural  SBP  sig-
iﬁcantly  predicted  a 12-month  outcome  of  SBP  <140  mmHg
P  <  0.05).  All  the  other  variables  tested  failed  to  reach
igniﬁcance  (all  P-values  >0.05).  Multivariable  analysis  was
herefore  not  performed.
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Results
Study population
Over  a  7-year  period,  a  total  of  54  consecutive  patients
underwent  CoA  stenting.  Five  patients  were  excluded,  as
they  did  not  attend  follow-up  appointments  within  the  spec-
iﬁed  time  periods  for  blood  pressure  monitoring.  Forty-nine
patients  had  complete  measurements;  their  mean  age  was
34  ±  16  years  (range:  15—72  years).  Patient  demographics,
lesion  characteristics  and  associated  conditions  are  given  in
Table  1.
Patients  were  followed  up  for  24  ±  17  months  (range:
3—65  months,  median:  17  months).  A  total  of  17/54  (31%)
patients  had  a  follow-up  angiogram,  while  the  rest  had  non-
invasive  assessment  using  a  computed  tomographic  scan.
One  patient  had  successful  redilatation  of  his  stent  28
months  later  for  stent  recoil  with  increasing  gradients.  No
other  patient  required  reintervention  for  the  CoA,  and  there
was  no  evidence  of  aneurysm  formation.  One  patient  needed
deployment  of  a  covered  stent  because  of  fracture  of  stent
struts  in  the  previously  deployed  stent.  Two  patients  under-
went  additional  cardiac  procedures  unrelated  to  the  CoA
stenting  procedure,  including  percutaneous  aortic  balloon
valvuloplasty  for  aortic  stenosis  (bicuspid  aortic  valve)  and
device  closure  of  a  left-sided  ascending  vein  for  partial
anomalous  pulmonary  venous  drainage  [17].
One  patient  had  a  stroke  5  months  after  the  procedure,
was  thrombolysed  and  made  a  satisfactory  recovery.  One
patient  underwent  successful  surgical  aortic  valve  replace-
ment  and  one  patient  underwent  mastectomy  for  carcinoma
Table  1  Patients’  demographics  and  associated  condi-
tions  (n  =  54).
Variable
Men  36
Age  (years)  34  ±  16
Native  CoA  35
Previous  surgical  repair  14
Previous  balloon  dilatation  10
Stent  strut  fracture  in  previous  CoA  stent  1
Associated  conditions
Bicuspid  aortic  valve  18
Ventricular  septal  defect  5
Atrial  ﬁbrillation  4
Atrial  septal  defect  3
Turner’s  syndrome 3
Patent  ductus  arteriosus 3
Wolff-Parkinson-White  syndrome  2
Cerebral  aneurysm  1
Dextrocardia  1
Parachute  malformation  of  mitral  valve  1
Dysplastic  aorta  1
Waardenberg’s  syndrome  1
Data are expressed as number or mean ± standard deviation;
CoA: aortic coarctation.
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f  breast  in  the  follow-up  period.  There  was  one  death  in  the
ollow-up  period  resulting  from  non-cardiac  causes.
rocedural data
revious  balloon  dilatations  had  been  performed  in  10
atients.  Two  patients  had  undergone  three  previous  balloon
ilatation  procedures  each.  None  of  these  was  performed  as
art  of  the  stenting  procedure.  Covered  stents  were  used  in
0  (74%)  patients:  the  CP  StentTM was  used  in  24/54  (44%)
atients  and  the  Adventa  V12TM stent  was  used  in  16/54
30%)  patients.  Uncovered  stents  were  used  in  14  (26%)
atients:  the  CP  StentTM, the  Max  LDTM and  the  JOSTENTTM
Abbott  Vascular  Devices,  Santa  Clara,  CA,  USA)  were  used  in
1  patients,  2  patients  and  1 patient,  respectively.  The  stent
ength  varied  from  28  to  40  mm.  In  40/54  (74%)  patients  the
emoral  access  site  was  closed  using  a  preclosure  technique
ith  a  PercloseTM closure  device.  Femoral  artery  sheath  sizes
anged  from  10—14  Fr  (French).
omplications
here  was  no  procedure-related  mortality  or  need  for
mergency  cardiac  or  vascular  surgery.  All  patients  were
obilized  within  6  hours  after  the  procedure,  except  one
atient  who  had  a  femoral  artery  dissection,  which  was
uccessfully  managed  conservatively.  None  of  the  patients
ad  an  endovascular  leak  after  intervention.  Major  vascular
ccess  site  complication  was  seen  in  one  additional  patient,
ho  developed  an  arteriovenous  ﬁstula  that  was  diagnosed
 weeks  after  the  stenting  procedure  and  required  vascular
urgical  repair.  There  was  one  non-cardiac  related  death,
ut  no  cardiac  mortality  in  the  follow-up  period.  One  patient
ith  a  very  tortuous  aorta  had  stent  embolization;  this  stent
as  safely  redeployed  in  the  descending  abdominal  aorta.
eak-to-peak systolic gradientshere  was  a  weak  but  signiﬁcant  linear  correlation  between
aseline  PG  and  baseline  SBP  (r  =  0.45;  P  =  0.001;  Fig.  1).
here  was  a  signiﬁcant  fall  in  PG  across  the  CoA  after
igure 1. There was a weak but signiﬁcant linear correlation
etween baseline peak gradient (PG) across aortic coarctation and
aseline systolic blood pressure (SBP) in the right arm (r = 0.45;
 = 0.001). The line of best ﬁt is shown in black.
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Table  2  Correlations  between  peak  gradient  reduction
and  systolic  blood  pressure  reduction.
Correlation
coefﬁcient  ra
P
Correlation  with  absolute  PG  reduction
SBP  reduction  at  6—12  weeks  0.21  0.14
SBP  reduction  at  6—12  months  −0.01  0.94
Correlation  with  percentage  PG  reduction
SBP  reduction  at  6—12  weeks 0.03  0.83
SBP  reduction  at  6—12  months −0.11 0.46
PG: peak gradient across aortic coarctation; SBP: systolic blood
pressure in right upper limb.
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sigure 2. Individual changes in peak gradient across aortic coarc-
ation immediately after stenting.
tenting,  from  26  ±  11  mmHg  (range:  10—50  mmHg)  to
 ±  4  mmHg  (range:  0—20  mmHg;  P  <  0.01).  The  changes  in
G  for  individual  lesions  are  shown  in  Fig.  2.
lood pressure outcomes
here  was  a  signiﬁcant  reduction  in  baseline  SBP  from
55  ±  18  to  137  ±  17  mmHg  at  6—12  weeks  (P  <  0.01;  n  =  50)
nd  to  142  ±  16  mmHg  (P  =  0.001)  at  9—12  months  (n  =  47)
fter  stenting.  There  was  a  signiﬁcant  reduction  in
mbulatory  24-hour  SBP  from  142  ±  14  mmHg  at  baseline
o  132  ±  16  mmHg  at  6  weeks  (P  <  0.01;  n  =  41)  and  to
31  ±  15  mmHg  at  9—12  months  (P  =  0.003;  n  = 33)  after  sten-
ing.
There  was  no  signiﬁcant  difference  in  the  mean  number
f  antihypertensive  medications  used  before  and  after  sten-
ing  in  the  study  population  overall  (1.9  ±  0.7  vs.  1.7  ±  0.6;
 =  0.68),  or  speciﬁcally  in  those  patients  on  antihyperten-
ive  medication  at  baseline  (n  =  35;  1.8  ±  0.7  vs.  1.8  ±  0.7;
 =  0.38).  Fifteen  patients  were  normotensive  at  baseline
ithout  needing  antihypertensive  treatment.  Similarly,  four
atients  had  clinical  SBP  ≥150  mmHg  preprocedure  and  pre-
erred  to  wait  for  the  intervention  procedure  before  starting
ntihypertensive  treatment.  These  four  patients  went  on  to
ave  antihypertensive  therapy  at  12-month  follow-up  after
oA  stenting,  despite  an  excellent  gradient  reduction  (resid-
al  gradient  <10  mmHg)  in  all  cases,  as  their  blood  pressure
as  not  in  the  target  range  (140/90  mmHg)  at  6-week  follow-
p.  One  of  these  patients  also  had  Turner’s  syndrome  with  a
ypoplastic  arch.
The  antihypertensive  treatments  used  included  beta-
lockers,  angiotensin-converting  enzyme  inhibitors  and
alcium  channel  blockers.
There  were  no  signiﬁcant  correlations  between  reduc-
ion  in  PG  after  stenting  (absolute  or  percentage  change)
nd  reductions  in  SBP  at  6—12  weeks  or  at  9—12  months
ompared  with  baseline  (Table  2).  On  ROC  analysis,  neither
he  absolute  nor  the  percentage  PG  reduction  after  stenting
a
s
t
tPearson’s correlation coefﬁcient.
igniﬁcantly  predicted  adequate  control  of  SBP  at  6  weeks
AUC  0.62  and  0.51,  respectively)  or  at  6  months  (AUC  0.47
nd  0.54,  respectively;  all  95%  CIs  traversed  zero  and  all
-values  were  >0.10;  Fig.  3).
evere versus non-severe aortic coarctation
wenty-four  patients  were  classiﬁed  as  having  severe  CoA
PG  >25  mmHg)  and  25  as  having  non-severe  CoA  (PG
25  mmHg)  before  stenting.  The  severe  CoA  group  had  a
igniﬁcantly  higher  SBP  at  baseline  compared  with  the  non-
evere  group  (160  vs.  148  mmHg;  P  =  0.02).  After  stenting,
he  absolute  reduction  in  PG  was  signiﬁcantly  higher  in
he  severe  versus  the  non-severe  group  (31  ±  7  mmHg  vs.
4  ±  5  mmHg;  P  <  0.0001),  but  there  was  no  signiﬁcant  dif-
erence  in  the  percentage  PG  change  between  the  two
roups  (84  ±  12%  vs.  77  ±  19%;  P  =  0.12).  At  6  weeks,  there
as  no  signiﬁcant  difference  in  SBP  between  the  severe
nd  non-severe  groups  (141  mmHg  vs.  135  mmHg;  P  =  0.21),
nd  this  remained  the  case  at  9—12  months  (139  mmHg  vs.
39  mmHg;  P  =  0.96).
iscussion
he  management  of  CoA  is  mainly  focused  on  gradient
eduction,  and  the  effect  on  hypertension,  especially  in
dults,  is  not  well  described.  This  study  demonstrates  that
ranscatheter  treatment  for  CoA  in  adolescents  and  adults
ith  primary  stenting  results  in  immediate  and  sustained
aemodynamic  beneﬁts.  Speciﬁcally,  the  main  ﬁndings  were
hat  there  was  a  signiﬁcant  immediate  reduction  in  abso-
ute  and  percentage  PG  across  the  CoA  after  stenting  in
eeping  with  previous  studies  [14,16,18—20],  which  trans-
ated  into  a signiﬁcant  reduction  in  SBP  at  6  weeks  and  9—12
onths,  but  that  there  was  a  need  to  maintain  medical  ther-
py.  Another  important  ﬁnding  was  that  the  SBP  proﬁles  of
evere  and  non-severe  CoA  seem  to  equilibrate  at  6  weeks
ost-procedure,  and  this  was  maintained  at  9—12  months,
uggesting  that  both  groups  may  follow  a  similar  risk  proﬁle
fter  intervention  rather  than  continuing  to  diverge.  This
uggests  that  patients  with  non-severe  CoA,  as  deﬁned  in
his  study,  may  derive  beneﬁt  in  terms  of  hypertension  con-
rol  with  stenting  of  aortic  coarctation,  but  this  will  require
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Figure 3. On receiver-operating characteristic analysis, neither the absolute (A, B) nor the percentage reduction (C, D) in peak gradient
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t(PG) across aortic coarctation after stenting signiﬁcantly predicted a
AUC: area under the curve; CI: conﬁdence interval.
further  large-scale  clinical  validation  and  a  longer  follow-up
duration.  Finally,  the  study  also  showed  that  the  initial  PG
reduction  (absolute  or  percentage  change)  is  not  an  accurate
predictor  of  whether  normal  SBP  (<140/90)  will  be  achieved
in  the  long-term,  and  that  other  factors  therefore  need  to
be  considered  and  studied  in  the  future.
Arterial  hypertension  has  been  associated  with  increased
morbidity  and  mortality  from  cardiovascular  disease  [21].  A
study  by  Hager  et  al.  [22]  (n  =  404)  showed  persistent  hyper-
tension  in  patients  who  underwent  surgical  repair  in  >50%
of  patients  at  a  follow-up  of  27  years.  Our  study  showed
signiﬁcant  improvement  in  hypertension  control  after  sten-
ting  in  the  immediate  period,  which  persisted  at  1  year.
Persistent  hypertension  after  CoA  repair  in  the  presence  or
absence  of  residual  stenosis  has  been  reported  [18], and  was
also  seen  in  our  patients.  While  there  was  a  trend  towards
a  decrease  in  the  number  of  antihypertensive  medications
after  stenting,  this  did  not  reach  signiﬁcance.  The  major-
ity  of  our  patients  continued  antihypertensive  therapy  for
m
w
tate control of systolic blood pressure (SBP) at 6 weeks or 6 months.
ptimal  control,  as  has  been  described  previously  [13,15].
he  residual  prevalence  of  hypertension  after  CoA  stenting
ay  be  multifactorial,  including  morphology  of  the  arch,
ge,  poor  arterial  compliance,  the  change  in  target  blood
ressure  guidance  [23—25]  and  the  effect  of  recurrent  CoA.
imilarly,  our  results  showed  that  those  patients  who  were
ot  on  any  medication  before  intervention  remained  nor-
otensive,  with  the  need  for  antihypertensive  medication
n  only  four  patients.  Of  those  with  established  hyperten-
ion,  ﬁve  had  their  antihypertensive  treatments  stopped,
ndicating  that  it  is  may  be  possible  to  cease  therapy  with
ntihypertensive  medication  after  stenting.
There  is  evidence  in  the  adult  literature  that  24-hour
lood  pressure  is  a  better  predictor  of  end  organ  damage,
nd  therefore  provides  a  better  measure  of  blood  pressure
han  casual  readings  [26].  Our  study  demonstrated  improve-
ent  in  24-hour  blood  pressure  compared  with  baseline,
hich  was  sustained  at  9—12  months,  and  it  is  possible  that
his  may  be  of  prognostic  beneﬁt  in  the  long-term.
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Surgery  for  CoA  and  recurrent  CoA  has  been  associated
ith  complications,  including  death,  stroke,  infection,  true
nd  false  aneurysm  formation,  rupture  of  the  anastomosis
ausing  a  pseudoaneurysm,  spinal  cord  damage  (including
araplegia;  0.3%),  unusual  gait  and  aortic  dissection  and
ocal  cord  palsy  [27—30].  Similarly,  there  is  a  risk  of  occlu-
ion  of  the  left  subclavian  artery  or  occlusion  of  other
ranches  of  the  aorta  [31]  with  covered  stents.  Strut  frac-
ure  has  been  reported  with  uncovered  CoA  stents  [32—34],
s  well  as  aortic  dissection  or  rupture.  One  of  our  patients
eveloped  a  strut  fracture  in  a  previously  implanted  stent,
hich  was  successfully  treated  with  implantation  of  a  cov-
red  CP  StentTM.
The  majority  of  our  patients  underwent  stenting  using
 covered  stent,  which  may  decrease  but  not  eliminate
he  risk  of  aortic  perforation  [35].  Previous  studies  have
emonstrated  the  safety  of  CoA  stenting  in  children  [25,36].
 review  study  (comparison  between  angioplasty  [n  =  633]
nd  surgery  [n  =  213])  by  Carr  [37]  showed  a  lower  inci-
ence  of  restenosis  and  recurrence  in  surgically  treated
atients,  while  CoA  stenting  has  been  associated  with  the
owest  morbidity.  Currently,  based  on  the  available  litera-
ure  [13,14,16,18—20],  primary  stent  deployment  in  native
r  recurrent  CoA  patients  may  be  considered  as  ﬁrst-line
herapy  in  most  adolescent  and  adult  patients  with  CoA.
Our  patients  underwent  additional  procedures  after  CoA
tenting,  including  percutaneous  aortic  balloon  valvulo-
lasty  for  aortic  stenosis  and  partial  anomalous  pulmonary
enous  drainage  device  closure  [38],  aortic  valve  replace-
ent  and  mastectomy  for  carcinoma  of  breast,  without  any
ardiovascular  issues  related  to  the  CoA.
tudy limitations
his  was  a  cohort  study,  reﬂecting  the  fact  that  these  data
re  derived  from  real-world  practice  in  a  selected  group
f  patients.  There  was  no  controlled  or  regulated  antihy-
ertensive  regimen  or  strategy  (i.e.  clinician  choice  was
sed  in  the  prescription  of  antihypertensive  treatment).
e  did  not  have  a  control  arm  comprising  medical  therapy
lone.  As  many  patients  were  referred  from  outside  hospi-
als  to  our  institution  for  specialist  procedural  treatment,
dditional  background  data  on  the  study  group,  including
uration  of  hypertension,  left  ventricular  hypertrophy  and
enin/aldosterone  status,  was  not  complete  in  all  patients  to
nclude  in  the  analyses.  As  it  generally  takes  longer  than  the
resented  12  months  of  data  to  safely  scale  down  antihyper-
ensive  treatment  and  to  reassess  for  long-term  success  and
reedom  from  hypertension  treatment,  such  analyses  are  the
ubject  of  ongoing  work  to  be  reported  in  the  future.
onclusion
his  study  demonstrates  that  stenting  of  both  native  and
ecurrent  CoA  in  adults  results  in  a  signiﬁcant  reduction  in
BP  6  weeks  after  the  procedure,  which  is  sustained  after year.  While  there  is  a  continuing  need  for  antihyperten-
ive  therapy,  even  patients  with  non-severe  CoA  undergoing
tenting  appear  to  beneﬁt  from  better  control  of  systemic
ypertension.
[T.  Hamid  et  al.
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